Sunesis Pharmaceuticals (SNSS) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500, Nasdaq set for lower open as AI stocks slide on debt concerns
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent oil slips as US weighs easing sanctions on Russia's 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Walmart stock: Deutsche Bank gets bullish amid pricing tailwinds
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Join SI Premium – FREE
Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q4 EPS of ($0.44), $0.01 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $600 thousand.
For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ManpowerGroup (MAN) Reports In-Line Q3 EPS; offers guidance
- AZZ, Inc. (AZZ) Tops Q2 EPS by 15c; raises guidance
- Marsh shares rise 2% after beating third quarter estimates on strong revenue growt
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
